Amneal Pharmaceuticals (NASDAQ:AMRX) Cut to “Hold” at Zacks Research

Zacks Research downgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a strong-buy rating to a hold rating in a research report report published on Monday,Zacks.com reports.

AMRX has been the topic of a number of other reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Truist Financial lifted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Barclays started coverage on Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.20.

Amneal Pharmaceuticals Stock Up 3.2%

NASDAQ:AMRX opened at $12.71 on Monday. The business’s 50-day moving average price is $13.40 and its 200 day moving average price is $12.32. The firm has a market cap of $4.00 billion, a P/E ratio of 55.26 and a beta of 1.32. Amneal Pharmaceuticals has a 52-week low of $6.68 and a 52-week high of $15.42.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Spire Wealth Management raised its holdings in Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares during the period. Intech Investment Management LLC raised its holdings in Amneal Pharmaceuticals by 1.2% during the 4th quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after buying an additional 1,159 shares during the period. Hsbc Holdings PLC raised its holdings in Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after buying an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after buying an additional 1,582 shares during the period. Finally, Comerica Bank raised its holdings in Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after buying an additional 1,685 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.